Curis stock touches 52-week low at $2.83 amid sharp yearly decline

Curis Inc. (NASDAQ:CRIS), a biotechnology company focused on developing innovative therapeutics with a market capitalization of $24 million, saw its stock price touch a 52-week low, dipping to $2.83. According to InvestingPro analysis, the company’s current price suggests it may be undervalued, though investors should note its "Weak" overall financial health score. This latest price movement underscores a challenging period for the company, which has experienced a significant downturn over the past year, with its stock value plummeting by nearly 70%. With a beta of 3.49, the stock has shown high volatility, and the company’s gross profit margins remain negative at -287%. Investors have been closely monitoring Curis’s performance, particularly in the context of its drug development pipeline and market dynamics that have impacted the biotech sector at large. The 52-week low serves as a critical marker for the company, reflecting investor sentiment and the ongoing evaluation of its potential to rebound and deliver on its strategic goals. For deeper insights into Curis’s financial health and detailed analysis, access the comprehensive Pro Research Report available exclusively on InvestingPro.

In other recent news, Curis Inc has reported promising results from its TakeAim Leukemia study, focusing on the treatment of Acute Myeloid Leukemia (AML) with its drug candidate emavusertib. The study involved 21 patients, with 19 evaluable for response, and revealed 10 objective responses, including six complete remissions. These results are particularly significant given the rapid response observed in seven of the ten cases by the first assessment. Additionally, emavusertib has received Orphan Drug Designation for AML and MDS treatment in the U.S. and for PCNSL treatment in Europe, highlighting its potential impact.

In other developments, Curis Inc faces a potential Nasdaq delisting due to non-compliance with the market value requirements. The company has been notified that its market value has fallen below the $35 million threshold for 30 consecutive business days. Curis Inc has until August 2025 to regain compliance by maintaining the required market value for at least ten consecutive business days. Failure to meet this requirement could lead to the delisting of its common stock from the Nasdaq Capital Market. These recent developments are critical for investors as they evaluate Curis Inc’s ongoing progress and challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.